BACKGROUND: Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy. METHODS: We conduc...
BACKGROUND: The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physicians choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related qu...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO ...
BACKGROUND: MEDI7247 is a first-in-class antibody-drug conjugate (ADC) consisting of an anti-sodium-dependent alanine-serine-cysteine transporter 2 antibody-conjugated to a pyrrolobenzodiazepine dimer. OBJECTIVE: This first-in-human phase 1 trial evaluated MEDI7247 in patients with hematological malignancies. PATIENTS AND METHODS: Adults with acute...
Polatuzumab vedotin (Pola-V) is an antibody-drug conjugate directed to the CD79B subunit of the B-cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V improves outcomes in diffuse large B-cell lymphoma (DLBCL). To identify determinants of Pola-V sensitivity, we used CRISPR-Cas9 screening for genes that modulated Pola-V to...
Publication status: Published / Selective cleavage of amide bonds holds prominent significance by facilitating precise manipulation of biomolecules, with implications spanning from basic research to therapeutic interventions. However, achieving selective cleavage of amide bonds via mild synthetic chemistry routes poses a critical challenge. Here, w...
Acknowledgements: Special thanks and gratitude go to the BRU core facility (CRUK Cambridge Institute) for excellent animal husbandry, the Preclinical Imaging Core (CRUK Cambridge Institute) and especially Aude Vernet for help with in vivo imaging, the Histopathology core (CRUK Cambridge Institute) and especially Jodi Miller for help with establishi...
Acknowledgements: Special thanks and gratitude go to the BRU core facility (CRUK Cambridge Institute) for excellent animal husbandry, the Preclinical Imaging Core (CRUK Cambridge Institute) and especially Aude Vernet for help with in vivo imaging, the Histopathology core (CRUK Cambridge Institute) and especially Jodi Miller for help with establishi...
Published in Journal of Gynecologic Oncology
In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 in...
Published in Journal of Gynecologic Oncology
This review highlights the practice-changing trials of cervical cancer systemic therapies in 2023. New standards of care in locally advanced and persistent, recurrent, or metastatic disease are presented. Lastly, we outline future research directions which can inform selection and sequencing of emerging therapeutics.
